The progression towards a pan-European HTA framework will pose new challenges to device and diagnostics companies as they contend with a heightened focus on higher quality evidence, with unchanged local decisionmaking around reimbursement. This session will explore concepts in evidence development for medical technologies, and how European payment systems have evolved to demand greater clinical and economic value than ever before.
Principal and Founder
Hull Associates, USA
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of NextLevel Life Sciences.